• LAST PRICE
    1.7500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.7000/ 81
  • Ask / Lots
    2.0000/ 20
  • Open / Previous Close
    0.0000 / 1.7500
  • Day Range
    ---
  • 52 Week Range
    Low 1.7100
    High 11.4000
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.8
TimeVolumeAPS
09:32 ET8001.82
10:01 ET11001.75
10:06 ET21001.71
12:48 ET12001.8
03:57 ET1001.75
03:59 ET2001.75
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaAPS
Aptose Biosciences Inc
27.6M
-0.2x
---
CanadaHUGE
FSD Pharma Inc
28.0M
-1.1x
---
CanadaBMND
Biomind Labs Inc
28.0M
-14.0x
---
CanadaTTI
Thiogenesis Therapeutics Corp
32.3M
-8.0x
---
CanadaNRX
Nurexone Biologic Inc
32.7M
-5.0x
---
CanadaHBP
Helix Biopharma Corp
46.0M
-7.0x
---
As of 2024-04-17

Company Information

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Contact Information

Headquarters
251 Consumers Rd Suite 1105NORTH YORK, ON, Canada M2J 4R3
Phone
647-479-9828
Fax
416-798-2200

Executives

Chairman of the Board, President, Chief Executive Officer
William Rice
Chief Financial Officer, Senior Vice President, Chief Business Officer
Fletcher Payne
Senior Vice President, Chief Medical Officer
Rafael Bejar
Senior Vice President, Chief Commercial Officer
Philippe Ledru
Lead Independent Director
Denis Burger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$27.6M
Revenue (TTM)
$0.00
Shares Outstanding
15.7M
Aptose Biosciences Inc does not pay a dividend.
Beta
1.46
EPS
$-10.74
Book Value
$-0.51
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.